case_images: PMC10469684_01
case_images: Myocardial thickening and dilated atria in the parasternal long axis and in the apical four chamber view.
case_images: fcvm-10-1224578-g001.jpg
case_images: PMC10469684_01_fcvm-10-1224578-g001.jpg
case_images: F1
case_images: Echocardiogram demonstrated left ventricular thickening, preserved left ventricular systolic ejection fraction (LVEF 60%), a dilated left atrium (left atrial volume 94 ml), minimal residual mitral valve regurgitation (status post MitraClip placement) and normal left ventricular size (Figure 1).
case_images: Amyloid deposits in the patient's biopsy. Courtesy of Dirk Lassner, IKDT.
case_images: fcvm-10-1224578-g002.jpg
case_images: PMC10469684_01_fcvm-10-1224578-g002.jpg
case_images: F2
case_images: Endomyocardial biopsy revealed cardiac TTR deposits (Figure 2).
case_images: Magnetocardiography (MCG) measurements from March 2019 to June 2021 during treatment with tafamidis for ATTRwt amyloidosis.
case_images: fcvm-10-1224578-g003.jpg
case_images: PMC10469684_01_fcvm-10-1224578-g003.jpg
case_images: F3
case_images: Before initiation of therapy, an MCG measurement was performed and was found to be pathological with a value of 0.052 (Figure 3). A chronological overview of the MCG measurements over the course of 2 years is provided in Figure 3.
case_images: Overview of (A) NT-proBNP (ng/L) and (B) cardiac troponin T (cTnT, ng/L) levels from February 2019 to July 2021 as well as (C) summary of the time-variation for all parameters.
case_images: fcvm-10-1224578-g004.jpg
case_images: PMC10469684_01_fcvm-10-1224578-g004.jpg
case_images: F4
case_images: Performance of longitudinal strain analysis was unfortunately limited in this patient due to atrial fibrillation. cTnT and NT-proBNP serum levels were abnormal with cTnT ranging from 33 to 57 ng/L and NT-proBNP ranging from 1,730 to 3,621 ng/L between visits (Figure 4), with an overall downward trend and intermittent peaks.